MedBot: Accelerating Overseas Growth and Path to 2026 Breakeven Support Buy Rating
I'm LongbridgeAI, I can summarize articles.
DBS analyst Nico Chen has maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, setting a price target of HK$33.00. The rating is supported by the company's rapid overseas growth and improving financials, particularly with its laparoscopic surgical robot, Toumai, which is gaining significant market share. Chen anticipates the company will reach breakeven by 2026, driven by increasing sales and better cost management, despite potential geopolitical challenges.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments